Ibogaine Therapy — Psychedelics & Neuroplasticity
African psychedelic alkaloid with unique addiction-interrupting and neuroplasticity properties — single session can eliminate opioid withdrawal and produce weeks-to-months of craving reduction.
Overview
Ibogaine is a naturally occurring psychoactive alkaloid from Tabernanthe iboga root bark, used in Bwiti spiritual ceremonies in Central Africa. Its pharmacology is uniquely complex: NMDA antagonist, kappa-opioid agonist, sigma-2 receptor agonist, voltage-gated sodium channel blocker, and serotonin reuptake inhibitor. Most remarkably, a single high-dose ibogaine session dramatically attenuates opioid withdrawal symptoms (typically rated as one of the most unbearable medical experiences) and reduces opioid, alcohol, cocaine, and methamphetamine cravings for weeks to months. A 2023 Stanford study (n=30 veterans with TBI + opioid issues) showed ibogaine significantly improved PTSD, depression, anxiety, and disability scores with excellent safety under medical supervision. Phase 2 clinical trials for opioid use disorder are underway (MAPS, universities). The cardiac risk (ibogaine blocks hERG potassium channels, prolonging QT interval → risk of torsades de pointes) requires mandatory ECG screening and cardiac monitoring and is the primary safety concern. Mexico, Canada (via Health Canada Special Access), and several other countries allow access.
Indications
- Opioid use disorder (strongest evidence for withdrawal mitigation and craving reduction)
- Alcohol use disorder
- Cocaine and methamphetamine addiction
- PTSD with trauma (veteran data)
- Treatment-resistant depression (case reports and open label)
Mechanism of Action
Ibogaine simultaneously blocks NMDA receptors (like ketamine), inhibits serotonin and dopamine reuptake, acts as kappa-opioid agonist, and blocks sigma receptors — a pharmacological profile that disrupts addiction neural circuitry through multiple simultaneous mechanisms
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Ibogaine HCl (medical protocol) | 10-20 mg/kg (typical: 15-17 mg/kg for opioid use disorder) | Single session; booster dose may be given 8-16 hours later | Must be administered in medical facility with ICU-capable cardiac monitoring; not available legally in USA; clinics in Mexico, Canada |
| Ibogaine (flood dose microtaper) | 5-10 mg/kg (lower dose with weekly boosters) | Initial flood + 1-3 mg/kg boosters every 1-3 weeks for 4-6 weeks | Emerging protocol for addiction treatment with lower single-dose risk; evidence base less developed than flood dose |
Evidence Grade
GRADE C
Safety & Contraindications
- CRITICAL CARDIAC RISK: Ibogaine prolongs QT interval — can cause fatal torsades de pointes arrhythmia; estimated 1-in-300 mortality in unscreened populations
- Mandatory pre-treatment requirements: 12-lead ECG (QTc must be < 450ms), cardiac history review, electrolyte normalization (potassium, magnesium)
- Monitor with continuous telemetry during and 24 hours after administration
- Drug interactions: concurrent opioids, benzodiazepines, antidepressants, methadone (extremely long half-life — requires 1 week washout minimum)
- Duration is 18-36 hours (waking dream state) — extreme physical and psychological demands
- Hepatotoxicity reported at high doses — liver function testing pre-treatment
- Contraindications: cardiac disease, prolonged QT, hepatic disease, seizure disorder